InsightRX GEMINISM is designed to save clinician time and eliminate the need for manual model filtering SAN FRANCISCO , Aug. 27, 2024 /PRNewswire/ -- InsightRX – the leader in Bayesian model-informed precision dosing software – today announced the release of InsightRX GEMINISM. Privately released to select customers on July 30, 2024 , this enhanced dose-selection algorithm for vancomycin was built from datasets of 384,000+ patient treatment courses.
Clinical guidelines recommend dosing vancomycin based on area under the plasma drug concentration-time curve (AUC). AUC estimation accuracy is greatly dependent on the model and method used; which has been a time-consuming test and review process. In just one-click, InsightRX GEMINISM works by: InsightRX's new algorithm is based on experience and research, following seven years of applying model-informed precision dosing (MIPD) to treat over one million patients.
InsightRX GEMINISM automates the selection of the most effective vancomycin PK model at the start of therapy, using patient characteristics known to impact model performance, like body mass index (BMI) and age. Auto-selected models can reduce bias, and result in better overall performance – ensuring a consistent best-practice standardization across healthcare systems. External validation of the algorithm in a separate dataset of 144,000 patients showed that following the InsightRX GEMINISM model selection increased model prediction accuracy by as much as 47% from ba.